Q1 2025 Nektar Therapeutics Earnings Call Transcript

May 8, 2025 / 09:00 PM GMT

Release Date Price: MXN255

Transcript 10-Q8-K

Key Points

Positve

Nektar Therapeutics (NKTR) is advancing its immunology pipeline, focusing on ResPEGaldu leukin (ResPEG) in three separate phase 2 studies.
The company plans to share top-line results from a 400-patient phase 2b study for ResPEG in atopic dermatitis in June 2025.
Nektar Therapeutics (NKTR) is in a strong financial position with a cash runway extending into the fourth quarter of 2026.
The company is progressing with IND enabling studies for its TNFR2 agonist antibody program, Nectar 165, and expects to submit an IND filing in 2025.
Nektar Therapeutics (NKTR) has a collaboration with the Fred Hutchinson Cancer Center, with data from their study being presented at the European Hematology Association congress.

Negative

Nektar Therapeutics (NKTR) reported a net loss of $50.9 million for the first quarter of 2025.
The company's revenue for the first quarter was $10.5 million, primarily from non-cash royalty revenue, and is expected to remain at similar levels throughout 2025.
There is uncertainty regarding the placebo response rate in the phase 2b study for atopic dermatitis, which could impact the study's outcomes.
Nektar Therapeutics (NKTR) acknowledges it may not have the financial capacity to execute a full phase 3 program without a partner.
The company is involved in litigation with Lilly, which could pose additional risks and uncertainties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NKTR.OQ - Nektar Therapeutics
Q1 2025 Nektar Therapeutics Earnings Call
May 08, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Nectar Therapeutics first quarter 2025 Financial results conference call.

At this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question and answer session.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Corinne Franklin and Nectar Investor Relations, who is filling in for Vivian Wu, who is on maternity leave. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.